论文信息 - Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity - 字舞流文

Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity

E. Ricevuto | C. Ficorella | K. Cannita | Z. C. di Rocco | G. Porzio | G. Cianci | R. Morese | P. Lanfiuti Baldi | M. Morelli

[1] J. C. Schmitz,et al. Thymidylate synthase: a critical target for cancer chemotherapy. , 2002, Clinical colorectal cancer.

[2] G Milano,et al. © 1999 Cancer Research Campaign Article no. bjoc.1998.0098 Dihydropyrimidine dehydrogenase deficiency and , 2022 .

[3] D. Häussinger,et al. Cardiotoxicity of the antiproliferative compound fluorouracil. , 1999, Drugs.

[4] M. Friedrich,et al. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity. , 1998, British Journal of Cancer.

[5] M. Cwikiel,et al. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[6] M. Cwikiel,et al. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. , 1995, Scanning microscopy.

[7] Norbertus C. Robben,et al. The syndrome of 5‐fluorouracil cardiotoxicity. An elusive cardiopathy , 1993, Cancer.

[8] H. Bruckner,et al. Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers. , 1988, The American journal of medicine.